Information de reference pour ce titreAccession Number: | 01189012-200611000-00019.
|
Author: | Bays, Harold +1; Blonde, Lawrence 2; Rosenson, Robert 3
|
Institution: | (1)L-MARC Research Center, Medical Director/President, 3288 Illinois Avenue, Louisville, KY 40213, USA. (2)Ochsner Clinic Foundation, Director, Ochsner Diabetes Clinical Research Unit, Department of Internal Medicine, Section on Endocrinology, Associate Residency Program Director, 1514 Jefferson Highway, Brent House, Room 629, New Orleans, LA 70121, USA. (3)University of Michigan, Professor, Department of Medicine, Division of Cardiovascular Medicine, Ann Arbor, MI, USA.
|
Title: | Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients?.[Review]
|
Source: | Expert Review of Cardiovascular Therapy. 4(6):871-895, November 2006.
|
Abstract: | : An increase in bodyweight is generally associated with an increased risk of excessive fat-related metabolic diseases (EFRMD), including Type 2 diabetes mellitus, hypertension and dyslipidemia. However, not all patients who are overweight have EFRMD, and not all patients with EFRMD are significantly overweight. The adipocentric paradigm provides the basis for a unifying, pathophysiological process whereby fat gain in susceptible patients leads to fat dysfunction ('sick fat'), and wherein pathological abnormalities in fat function (adiposopathy) are more directly related to the onset of EFRMD than increases in fat mass (adiposity) alone. But just as worsening fat function worsens EFRMD, improved fat function improves EFRMD. Peroxisome proliferator-activated receptor-[gamma] agonists increase the recruitment, proliferation and differentiation of preadipocytes ('healthy fat') and cause apoptosis of hypertrophic and dysfunctional (including visceral) adipocytes resulting in improved fat function and improved metabolic parameters associated with EFRMD. Weight loss interventions, such as a hypocaloric diet and physical exercise, in addition to agents such as orlistat, sibutramine and cannabinoid receptor antagonists, may have favorable effects upon fat storage (lipogenesis and fat distribution), nutrient metabolism (such as free fatty acids), favorable effects upon adipose tissue factors involved in metabolic processes and inflammation, and enhanced 'cross-talk' with other major organ systems. In some cases, weight loss therapeutic agents may even affect metabolic parameters and adipocyte function independently of weight loss alone, suggesting that the benefit of these agents in improving EFRMD may go beyond their efficacy in weight reduction. This review describes how adiposopathy interventions may affect fat function, and thus improve EFRMD.
(C) 2006Expert Reviews, Ltd.
|
Author Keywords: | adiposopathy; diabetes; dyslipidemia; hypertension; obesity.
|
References: | 1 Bays H, Abate N, Chandalia M. Adiposopathy: Sick fat causes high blood sugar, high blood pressure, and dyslipidemia. Future Cardiol. 1(1), 39-59 (2005).
2 Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J. Clin.Endocrinol.Metab. 89(2), 463-478 (2004).
3 Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol. 1(4), 389-420 (2006). ** 'Sister' or complimentary paper to this manuscript.
4 Bays HE. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes. Res. 12(8), 1197-1211 (2004).
5 Bays H, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr. Atheroscler. Rep. 8(2), 144-156 (2006). * In order to treat many excessive fat-related metabolic diseases, it is best to focus therapy on correcting fat function, rather than solely upon body mass index.
6 Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J. Clin. Invest 99(10), 2416-2422 (1997).
7 Viguerie N, Vidal H, Arner P et al. Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia 48(1), 123-131 (2005).
8 Gurnell M. Peroxisome proliferator-activated receptor [gamma] and the regulation of adipocyte function: lessons from human genetic studies. Best Pract. Res. Clin. Endocrinol. Metab. 19(4), 501-523 (2005).
9 Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J. Clin.Endocrinol.Metab. 87(6), 2784-2791 (2002).
10 Jbilo O, Ravinet-Trillou C, Arnone M et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19(11), 1567-1569 (2005).
11 Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol. 69(2), 471-478 (2006).
12 Osei-Hyiaman D, Harvey-White J, Batkai S, Kunos G. The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes. (Lond) 30(Suppl. 1), S33-S38 (2006).
13 Pagotto U, Vicennati V, Pasquali R. The endocannabinoid system and the treatment of obesity. Ann. Med. 37(4), 270-275 (2005).
14 Serazin V, Dieudonne MN, Morot M, de Mazancourt P, Giudicelli Y. cAMP-positive regulation of angiotensinogen gene expression and protein secretion in rat adipose tissue. Am. J. Physiol. Endocrinol. Metab. 286(3), E434-E438 (2004).
15 Abate N, Garg A. Heterogeneity in adipose tissue metabolism: causes, implications and management of regional adiposity. Prog. Lipid Res. 34(1), 53-70 (1995).
16 Arner P. Regional differences in protein production by human adipose tissue. Biochem. Soc. Trans. 29(Pt 2), 72-75 (2001).
17 Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 23(2), 201-229 (2002).
18 Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21(6), 697-738 (2000). ** Fat depots differ with regard to metabolic functions and contribution to metabolic disease.
19 Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta 1500(1), 88-96 (2000).
20 McCarty MF. Modulation of adipocyte lipoprotein lipase expression as a strategy for preventing or treating visceral obesity. Med. Hypotheses 57(2), 192-200 (2001).
21 Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat. Clin. Pract. 3(1), 35-42 (2006).
22 Liese AD, Mayer-Davis EJ, Tyroler HA et al. Development of the multiple metabolic syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis risk in communities. Ann. Epidemiol. 7(6), 407-416 (1997).
23 Janssen I, Katzmarzyk PT, Ross R. Waist circumference and not body mass index explains obesity-related health risk. Am. J. Clin. Nutr. 79(3), 379-384 (2004).
24 Zhu S, Heymsfield SB, Toyoshima H, Wang Z, Pietrobelli A, Heshka S. Race-ethnicity-specific waist circumference cutoffs for identifying cardiovascular disease risk factors. Am. J. Clin. Nutr. 81(2), 409-415 (2005).
25 Baker AR, Silva NF, Quinn DW et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc. Diabetol. 5, 1 (2006).
26 Zamboni M, Armellini F, Turcato E et al. Effect of weight loss on regional body fat distribution in premenopausal women. Am. J. Clin. Nutr. 58(1), 29-34 (1993).
27 Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 26(11), 3148-3152 (2003).
28 Kay SJ, Fiatarone Singh MA. The influence of physical activity on abdominal fat: a systematic review of the literature. Obes. Rev. 7(2), 183-200 (2006).
29 Kopelman PG. The effects of weight loss treatments on upper and lower body fat. Int. J. Obes. Relat. Metab. Disord. 21(8), 619-625 (1997).
30 O'Leary VB, Marchetti CM, Krishnan RK, Stetzer BP, Gonzalez F, Kirwan JP. Exercise-induced reversal of insulin resistance in obese elderly is associated with reduced visceral fat. J. Appl. Physiol. 100(5), 1584-1589 (2006).
31 Ross R, Janssen I, Dawson J et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes. Res. 12(5), 789-798 (2004).
32 Larson-Meyer DE, Heilbronn LK, Redman LM et al. Effect of calorie restriction with or without exercise on insulin sensitivity, [beta]-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care 29(6), 1337-1344 (2006).
33 Miyashita Y, Koide N, Ohtsuka M et al. Beneficial effect of low carbohydrate in low calorie diets on visceral fat reduction in type 2 diabetic patients with obesity. Diabetes Res. Clin. Pract. 65(3), 235-241 (2004).
34 Tiikkainen M, Bergholm R, Rissanen A et al. Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. Am. J. Clin. Nutr. 79(1), 22-30 (2004).
35 Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27(1), 33-40 (2004).
36 Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw I. Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int. J. Obes. Relat. Metab. Disord. 22(Suppl. 1), S38-S40 (1998).
37 Despres JP. Intra-abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J. Endocrinol. Invest. 29(3 Suppl.), 77-82 (2006).
38 Roche R, Hoareau L, Bes-Houtmann S et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem. Cell Biol. 126(2), 177-187 (2006).
39 Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J. Clin. Endocrinol. Metab. 89(6), 2595-2600 (2004).
40 Wood IS, Trayhurn P. Adipokines and the signaling role of adipose tissue in inflammation and obesity. Future Lipidol. 1(1), 81-89 (2006). ** Abnormal release of adipocyte factors with obesity may increase a pro-inflammatory response that contributes to metabolic disease.
41 Heilbronn L, Smith SR, Ravussin E. Failure of fat cell proliferation, mitochondrial function and fat oxidation results in ectopic fat storage, insulin resistance and type II diabetes mellitus. Int. J. Obes. Relat. Metab. Disord. 28(Suppl. 4) S12-S21 (2004). * Impaired adipogenesis contributes to metabolic disease.
42 Fagot-Campagna A, Balkau B, Simon D et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int. J. Epidemiol. 27(5), 808-813 (1998).
43 de Jongh RT, Serne EH, Ijzerman RG, de Vries G, Stehouwer CD. Free fatty acid levels modulate microvascular function: relevance for obesity-associated insulin resistance, hypertension, and microangiopathy. Diabetes 53(11), 2873-2882 (2004). * Increased circulating free fatty acids (FFAs) increase blood pressure.
44 Egan BM. Insulin resistance and the sympathetic nervous system. Curr. Hypertens. Rep. 5(3), 247-254 (2003). * Adiposopathy may contribute to hypertension in many ways.
45 Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev. Cardiol. 6(4), 179-188 (2003).
46 Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ. Res. 96(10), 1042-1052 (2005). ** Fat dysfunction worsens dyslipidemia.
47 Bryson JM, King SE, Burns CM, Baur LA, Swaraj S, Caterson ID. Changes in glucose and lipid metabolism following weight loss produced by a very low calorie diet in obese subjects. Int. J. Obes. Relat. Metab. Disord. 20(4), 338-345 (1996).
48 Faraj M, Lu HL, Cianflone K. Diabetes, lipids, and adipocyte secretagogues. Biochem. Cell Biol. 82(1), 170-190 (2004).
49 Seshadri P, Samaha FF, Stern L, Chicano KL, Daily DA, Iqbal N. Free fatty acids, insulin resistance, and corrected qt intervals in morbid obesity: effect of weight loss during 6 months with differing dietary interventions. Endocr. Pract. 11(4), 234-239 (2005).
50 Corbi GM, Carbone S, Ziccardi P et al. FFAs and QT intervals in obese women with visceral adiposity: effects of sustained weight loss over 1 year. J. Clin. Endocrinol. Metab. 87(5), 2080-2083 (2002).
51 De Glisezinski I, Moro C, Pillard F et al. Aerobic training improves exercise-induced lipolysis in SCAT and lipid utilization in overweight men. Am. J. Physiol. Endocrinol. Metab. 285(5), E984-E990 (2003).
52 Esposito K, Pontillo A, Di Palo C et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 289(14), 1799-1804 (2003).
53 Marniemi J, Vuori I, Kinnunen V, Rahkila P, Vainikka M, Peltonen P. Metabolic changes induced by combined prolonged exercise and low-calorie intake in man. Eur. J. Appl. Physiol. Occup. Physiol. 53(2), 121-127 (1984).
54 Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am. J. Clin. Nutr. 81(6), 1298-1306 (2005).
55 Sasaki J, Shindo M, Tanaka H, Ando M, Arakawa K. A long-term aerobic exercise program decreases the obesity index and increases the high density lipoprotein cholesterol concentration in obese children. Int. J. Obes. 11(4), 339-345 (1987).
56 Williams PT, Krauss RM, Vranizan KM, Albers JJ, Wood PD. Effects of weight-loss by exercise and by diet on apolipoproteins A-I and A-II and the particle-size distribution of high-density lipoproteins in men. Metabolism 41(4), 441-449 (1992).
57 Slyper AH. Low-density lipoprotein density and atherosclerosis. Unraveling the connection. JAMA 272(4), 305-308 (1994).
58 DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes. Int. J. Clin. Pract. 143(Suppl.), 9-21 (2004). ** Increased circulating FFAs are metabolically 'toxic' and are an important mechanism as to why excessive body fat contributes to metabolic disease.
59 Boden G, Laakso M. Lipids and glucose in type 2 diabetes: what is the cause and effect? Diabetes Care 27(9), 2253-2259 (2004).
60 Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab. 31(1), 15-22 (2005).
61 Day C, Bailey CJ. Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. Int. J. Obes. Relat. Metab. Disord. 22(7), 619-623 (1998).
62 McLaughlin T, Abbasi F, Lamendola C, Kim HS, Reaven GM. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. Metabolism 50(7), 819-824 (2001).
63 Ravinet Trillou C, Arnone M, Delgorge C et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284(2), R345-R353 (2003).
64 Hissin PJ, Foley JE, Wardzala LJ et al. Mechanism of insulin-resistant glucose transport activity in the enlarged adipose cell of the aged, obese rat. J. Clin. Invest. 70(4), 780-790 (1982).
65 Norris SL, Zhang X, Avenell A et al. Long-term effectiveness of lifestyle and behavioral weight loss interventions in adults with type 2 diabetes: a meta-analysis. Am. J. Med. 117(10), 762-774 (2004). * Weight loss in obese patients improves glucose control and overall outcomes.
66 Aucott L, Poobalan A, Smith WC et al. Weight loss in obese diabetic and non-diabetic individuals and long-term diabetes outcomes-a systematic review. Diabetes Obes. Metab. 6(2), 85-94 (2004).
67 Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann. Intern. Med. 142(6), 403-411 (2005).
68 Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and Exercise Reduce Low-grade Inflammation and Macrophage Infiltration in Adipose Tissue but not in Skeletal Muscle in Severely Obese Subjects. Am. J. Physiol. Endocrinol. Metab. 290(5), E961-E967 (2005).
69 Straznicky NE, Louis WJ, McGrade P, Howes LG. The effects of dietary lipid modification on blood pressure, cardiovascular reactivity and sympathetic activity in man. J. Hypertens. 11(4), 427-437 (1993).
70 Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 45(6), 1035-1041 (2005). * Weight loss in obese patients modestly improves high blood pressure.
71 Ruano M, Silvestre V, Castro R et al. Morbid obesity, hypertensive disease and the renin-angiotensin-aldosterone axis. Obes. Surg. 15(5), 670-676 (2005).
72 Stone NJ, Kushner R. Effects of dietary modification and treatment of obesity. Emphasis on improving vascular outcomes. Med. Clin. North Am. 84(1), 95-122 (2000).
73 Chen AK, Roberts CK, Barnard RJ. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metabolism 55(7), 871-878 (2006).
74 Dahlman I, Linder K, Arvidsson Nordstrom E et al. Changes in adipose tissue gene expression with energy-restricted diets in obese women. Am. J. Clin. Nutr. 81(6), 1275-1285 (2005).
75 Kannisto K, Pietilainen KH, Ehrenborg E et al. Overexpression of 11[beta]-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J. Clin. Endocrinol. Metab. 89(9), 4414-4421 (2004).
76 Tomlinson JW, Moore JS, Clark PM, Holder G, Shakespeare L, Stewart PM. Weight loss increases 11[beta]-hydroxysteroid dehydrogenase type 1 expression in human adipose tissue. J. Clin. Endocrinol. Metab. 89(6), 2711-2716 (2004).
77 Valsamakis G, Anwar A, Tomlinson JW et al. 11[beta]-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89(9), 4755-4761 (2004).
78 Putignano P, Pecori Giraldi F, Cavagnini F. Tissue-specific dysregulation of 11[beta]-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome. J. Endocrinol. Invest. 27(10), 969-974 (2004).
79 Engeli S, Bohnke J, Feldpausch M et al. Regulation of 11[beta]-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes. Res. 12(1), 9-17 (2004).
80 Coutinho AE, Campbell JE, Fediuc S, Riddell MC. Effect of voluntary exercise on peripheral tissue glucocorticoid receptor content and the expression and activity of 11{[beta]}-HSD1 in the Syrian hamster. J. Appl. Physiol. 100(5), 1483-1488 (2005).
81 Wake DJ, Walker BR. 11 [beta]-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell Endocrinol. 215(1-2), 45-54 (2004).
82 Masuzaki H, Yamamoto H, Kenyon CJ et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112(1), 83-90 (2003).
83 Morton NM, Paterson JM, Masuzaki H et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 [beta]-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53(4), 931-938 (2004).
84 Walker BR. 11[beta]-hydroxysteroid dehydrogenase type 1 in obesity. Obes. Res. 12(1), 1-3 (2004).
85 Masuzaki H, Flier JS. Tissue-specific glucocorticoid reactivating enzyme, 11 [beta]-hydroxysteroid dehydrogenase type 1 (11 [beta]-HSD1) - a promising drug target for the treatment of metabolic syndrome. Curr. Drug Targets Immune Endocr. Metabol. Disord. 3(4), 255-262 (2003).
86 Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609(2), 127-143 (2003).
87 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89(6), 2548-2556 (2004). ** Fat health is important to metabolic health.
88 Ahren B, Havel PJ, Pacini G, Cianflone K. Acylation stimulating protein stimulates insulin secretion. Int. J. Obes. Relat. Metab. Disord. 27(9), 1037-1043 (2003).
89 Havel PJ. Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53(Suppl. 1) S143-S151 (2004).
90 Faraj M, Sniderman AD, Cianflone K. ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J. Lipid Res. 45(4), 657-666 (2004).
91 Maslowska M, Wang HW, Cianflone K. Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam. Horm. 70, 309-332 (2005).
92 Faraj M, Havel PJ, Phelis S, Blank D, Sniderman AD, Cianflone K. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 88(4), 1594-1602 (2003).
93 Sniderman AD, Cianflone KM, Eckel RH. Levels of acylation stimulating protein in obese women before and after moderate weight loss. Int. J. Obes. 15(5), 333-336 (1991).
94 Schrauwen P, Hesselink MK, Jain M, Cianflone K. Acylation-stimulating protein: effect of acute exercise and endurance training. Int. J. Obes.(Lond.) 29(6), 632-638 (2005).
95 Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J. Clin. Endocrinol. Metab. 89(2), 447-452 (2004).
96 Kopp HP, Krzyzanowska K, Mohlig M, Spranger J, Pfeiffer AF, Schernthaner G. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int. J. Obes.(Lond.) 29(7), 766-771 (2005).
97 Valsamakis G, McTernan PG, Chetty R et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 53(4), 430-434 (2004).
98 Balagopal P, George D, Yarandi H, Funanage V, Bayne E. Reversal of obesity-related hypoadiponectinemia by lifestyle intervention: a controlled, randomized study in obese adolescents. J. Clin. Endocrinol. Metab. 90(11), 6192-6197 (2005).
99 Merl V, Peters A, Oltmanns KM et al. Serum adiponectin concentrations during a 72-hour fast in over- and normal-weight humans. Int. J. Obes.(Lond.) 29(8), 998-1001 (2005).
100 Anderlova K, Kremen J, Dolezalova R et al. The influence of very-low-calorie-diet on serum leptin, soluble leptin receptor, adiponectin and resistin levels in obese women. Physiol. Res. 55(3), 277-283(2005).
101 Mousavinasab F, Tahtinen T, Jokelainen J et al. Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population. Endocrine 26(1), 65-69 (2005).
102 Xydakis AM, Case CC, Jones PH et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J. Clin. Endocrinol. Metab. 89(6), 2697-2703 (2004).
103 Nassis GP, Papantakou K, Skenderi K et al. Aerobic exercise training improves insulin sensitivity without changes in body weight, body fat, adiponectin, and inflammatory markers in overweight and obese girls. Metabolism 54(11), 1472-1479 (2005). * Physical exercise may have favorable effects upon metabolic parameters in overweight patients beyond effects upon weight loss alone.
104 Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J. Clin. Endocrinol. Metab. 88(9), 4130-4134 (2003).
105 Coatmellec-Taglioni G, Ribiere C. Factors that influence the risk of hypertension in obese individuals. Curr. Opin. Nephrol. Hypertens. 12(3), 305-308 (2003).
106 Rochlitz H, Akpulat S, Bobbert T et al. [Significance of biomarkers for metabolic syndrome during weight reduction]. Dtsch. Med. Wochenschr. 130(17), 1061-1066 (2005).
107 Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87(6), 2764-2769 (2002).
108 Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, Cianflone K. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur. J. Clin. Invest. 29(8), 679-686 (1999).
109 Miner JL. The adipocyte as an endocrine cell. J. Anim. Sci. 82(3), 935-941 (2004). ** Fat health is important to metabolic health.
110 Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP. Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity. Clin. Exp. Immunol. 108(3), 507-515 (1997).
111 Mavri A, Stegnar M, Krebs M, Sentocnik JT, Geiger M, Binder BR. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler. Thromb. Vasc. Biol. 19(6), 1582-1587 (1999).
112 Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism. Curr. Opin. Nephrol. Hypertens. 13(3), 325-332 (2004).
113 Engeli S, Bohnke J, Gorzelniak K et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45(3), 356-362 (2005).
114 Maeda S, Iemitsu M, Jesmin S, Miyauchi T. Acute exercise causes an enhancement of tissue renin-angiotensin system in the kidney in rats. Acta Physiol. Scand. 185(1), 79-86 (2005).
115 Rauramaa R, Kuhanen R, Lakka TA et al. Physical exercise and blood pressure with reference to the angiotensinogen M235T polymorphism. Physiol. Genomics 10(2), 71-77 (2002).
116 Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc. Natl Acad. Sci. USA 100(24), 14211-14216 (2003).
117 Morse SA, Bravo PE, Morse MC, Reisin E. The heart in obesity-hypertension. Expert Rev. Cardiovasc. Ther. 3(4), 647-658 (2005).
118 Karlsson C, Lindell K, Ottosson M, Sjostrom L, Carlsson B, Carlsson LM. Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83(11), 3925-3929 (1998).
119 Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35(6), 1270-1277 (2000).
120 Ferry G, Tellier E, Try A et al. Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J. Biol. Chem. 278(20), 18162-18169 (2003).
121 Boucher J, Quilliot D, Praderes JP et al. Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression. Diabetologia 48(3), 569-577 (2005).
122 Summers SA, Nelson DH. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 54(3), 591-602 (2005).
123 Sawai H, Domae N, Okazaki T. Current status and perspectives in ceramide-targeting molecular medicine. Curr. Pharm. Des 11(19), 2479-2487 (2005).
124 Miura A, Kajita K, Ishizawa M et al Inhibitory effect of ceramide on insulin-induced protein kinase Czeta translocation in rat adipocytes. Metabolism 52(1), 19-24 (2003).
125 Long SD, Pekala PH. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem. J 319(Pt 1) 179-184 (1996).
126 Chavez JA, Holland WL, Bar J, Sandhoff K, Summers SA. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J. Biol. Chem. 280(20), 20148-20153 (2005).
127 Adams JM, Pratipanawatr T, Berria R et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53(1), 25-31 (2004).
128 asimacopoulos-Jeannet F. Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes. Int. J. Obes. Relat. Metab. Disord. 28(Suppl. 4) S53-S57 (2004).
129 Helge JW, Dobrzyn A, Saltin B, Gorski J. Exercise and training effects on ceramide metabolism in human skeletal muscle. Exp. Physiol. 89(1), 119-127 (2004).
130 Gauthier B, Robb M, McPherson R. Cholesteryl ester transfer protein gene expression during differentiation of human preadipocytes to adipocytes in primary culture. Atherosclerosis 142(2), 301-307 (1999).
131 Bays H McKenney J Davidson M. Torcetrapib/Atorvastatin combination therapy. Expert Rev. Cardiovasc. Ther. 3(5), 789-820 (2005).
132 Ebenbichler CF, Laimer M, Kaser S et al. Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler. Thromb. Vasc. Biol. 22(9), 1465-1469 (2002).
133 Seip RL, Moulin P, Cocke T et al. Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler. Thromb. 13(9), 1359-1367 (1993).
134 Horowitz JF. Fatty acid mobilization from adipose tissue during exercise. Trends Endocrinol. Metab. 14(8), 386-392 (2003).
135 Large V, Reynisdottir S, Langin D et al. Decreased expression and function of adipocyte hormone-sensitive lipase in subcutaneous fat cells of obese subjects. J. Lipid Res. 40(11), 2059-2066 (1999).
136 Yeaman SJ. Hormone-sensitive lipase-new roles for an old enzyme. Biochem. J 379(Pt 1), 11-22 (2004).
137 Stich V, Harant I, De Glisezinski I et al. Adipose tissue lipolysis and hormone-sensitive lipase expression during very-low-calorie diet in obese female identical twins. J. Clin. Endocrinol. Metab. 82(3), 739-744 (1997).
138 Li Y, Bujo H, Takahashi K et al. Visceral fat: higher responsiveness of fat mass and gene expression to calorie restriction than subcutaneous fat. Exp. Biol. Med. 228(10), 1118-1123 (2003).
139 De Glisezinski I, Crampes F, Harant I et al. Endurance training changes in lipolytic responsiveness of obese adipose tissue. Am. J. Physiol. 275(6 Pt 1), E951-E956 (1998).
140 Lee DL, Sturgis LC, Labazi H et al. Angiotensin II Hypertension is Attenuated in Interleukin-6 Knockout Mice. Am. J. Physiol. Heart Circ. Physiol. 290(3), H935-940 (2005).
141 Orshal JM, Khalil RA. Interleukin-6 impairs endothelium-dependent NO-cGMP-mediated relaxation and enhances contraction in systemic vessels of pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286(6), R1013-R1023 (2004).
142 Garanty-Bogacka B, Syrenicz M, Syrenicz A, Gebala A, Lulka D, Walczak M. Serum markers of inflammation and endothelial activation in children with obesity-related hypertension. Neuro. Endocrinol. Lett. 26(3), 242-246 (2005).
143 Monzillo LU, Hamdy O, Horton ES et al. Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes. Res. 11(9), 1048-1054 (2003).
144 Bertile F, Criscuolo F, Oudart H, Le Maho Y, Raclot T. Differences in the expression of lipolytic-related genes in rat white adipose tissues. Biochem. Biophys. Res. Commun. 307(3), 540-546 (2003).
145 Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ. The biology of white adipocyte proliferation. Obes. Rev. 2(4), 239-254 (2001).
146 Siddals KW, Westwood M, Gibson JM, White A. IGF-binding protein-1 inhibits IGF effects on adipocyte function: implications for insulin-like actions at the adipocyte. J. Endocrinol. 174(2), 289-297 (2002).
147 Mauras N, Haymond MW. Are the metabolic effects of GH and IGF-I separable? Growth Horm. IGF Res. 15(1), 19-27 (2005).
148 Engstrom BE, Burman P, Holdstock C, Ohrvall M, Sundbom M, Karlsson FA. Effects of gastric bypass on the GH/IGF-I axis in severe obesity - and a comparison with GH deficiency. Eur. J. Endocrinol. 154(1), 53-59 (2006).
149 Butzow TL, Lehtovirta M, Siegberg R et al. The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women. J. Clin. Endocrinol. Metab. 85(9), 3271-3275 (2000).
150 Daly RM, Dunstan DW, Owen N, Jolley D, Shaw JE, Zimmet PZ. Does high-intensity resistance training maintain bone mass during moderate weight loss in older overweight adults with type 2 diabetes? Osteoporos. Int. 16(12), 1703-1712 (2005).
151 Havel PJ. Role of adipose tissue in body-weight regulation: mechanisms regulating leptin production and energy balance. Proc. Nutr. Soc. 59(3), 359-371 (2000).
152 Yildiz BO, Haznedaroglu IC. Rethinking leptin and insulin action: Therapeutic opportunities for diabetes. Int. J. Biochem. Cell Biol. 38, 820-830 (2005).
153 Persson-Sjogren S, Elmi A, Lindstrom P. Effects of leptin, acetylcholine and vasoactive intestinal polypeptide on insulin secretion in isolated ob/ob mouse pancreatic islets. Acta Diabetol. 41(3), 104-112 (2004).
154 Ceddia RB, Koistinen HA, Zierath JR, Sweeney G. Analysis of paradoxical observations on the association between leptin and insulin resistance. FASEB J. 16(10), 1163-1176 (2002).
155 Benomar Y, Rideau N, Crochet S, Derouet M, Taouis M. Leptin fully suppresses acetylcholine-induced insulin secretion and is reversed by tolbutamide in isolated perfused chicken pancreas. Horm. Metab. Res. 35(2), 81-85 (2003).
156 Zieba DA, Amstalden M, Maciel MN et al. Divergent effects of leptin on luteinizing hormone and insulin secretion are dose dependent. Exp. Biol. Med. 228(3), 325-330 (2003).
157 Frank LL, Sorensen BE, Yasui Y et al. Effects of exercise on metabolic risk variables in overweight postmenopausal women: a randomized clinical trial. Obes. Res. 13(3), 615-625 (2005).
158 Rosenbaum M, Goldsmith R, Bloomfield D et al. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J. Clin. Invest. 115(12), 3579-3586 (2005).
159 Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J. Hypertens. 24(5), 789-801 (2006).
160 Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of Dietary Weight Loss on Sympathetic Activity and Cardiac Risk Factors Associated with the Metabolic Syndrome. J. Clin. Endocrinol. Metab. 90(11), 5998-6005 (2005).
161 Oral EA, Simha V, Ruiz E et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346(8), 570-578 (2002).
162 Banks WA, Coon AB, Robinson SM et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes 53(5), 1253-1260 (2004).
163 Lofgren IE, Herron KL, West KL et al. Weight loss favorably modifies anthropometrics and reverses the metabolic syndrome in premenopausal women. J. Am. Coll. Nutr. 24(6), 486-493 (2005).
164 Stiegler P, Cunliffe A. The role of diet and exercise for the maintenance of fat-free mass and resting metabolic rate during weight loss. Sports Med. 36(3), 239-262 (2006).
165 Chu NF, Stampfer MJ, Spiegelman D, Rifai N, Hotamisligil GS, Rimm EB. Dietary and lifestyle factors in relation to plasma leptin concentrations among normal weight and overweight men. Int. J. Obes. Relat. Metab. Disord. 25(1), 106-114 (2001).
166 Suviolahti E, Reue K, Cantor RM et al. Cross-species analyses implicate lipin 1 involvement in human glucose metabolism. Hum. Mol. Genet. 15(3), 377-386 (2005).
167 Kern PA. Potential role of TNF[alpha] and lipoprotein lipase as candidate genes for obesity. J. Nutr. 127(9), 1917S-1922S (1997).
168 Couillard C, Bergeron N, Prud'homme D et al. Postprandial triglyceride response in visceral obesity in men. Diabetes 47(6), 953-960 (1998).
169 Shoji T, Nishizawa Y, Koyama H et al. Lipoprotein metabolism in normolipidemic obese women during very low calorie diet: changes in high density lipoprotein. J. Nutr. Sci. Vitaminol. (Tokyo) 37(Suppl.) S57-S64 (1991).
170 Kern PA, Ong JM, Saffari B, Carty J. The effects of weight loss on the activity and expression of adipose-tissue lipoprotein lipase in very obese humans. N. Engl. J. Med. 322(15), 1053-1059 (1990).
171 Berman DM, Nicklas BJ, Ryan AS, Rogus EM, Dennis KE, Goldberg AP. Regulation of lipolysis and lipoprotein lipase after weight loss in obese, postmenopausal women. Obes. Res. 12(1), 32-39 (2004).
172 Patalay M, Lofgren IE, Freake HC, Koo SI, Fernandez ML. The lowering of plasma lipids following a weight reduction program is related to increased expression of the LDL receptor and lipoprotein lipase. J. Nutr. 135(4), 735-739 (2005).
173 Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98(19), 2088-2093 (1998).
174 Kolehmainen M, Vidal H, Ohisalo JJ, Pirinen E, Alhava E, Uusitupa MI. Hormone sensitive lipase expression and adipose tissue metabolism show gender difference in obese subjects after weight loss. Int. J. Obes. Relat. Metab. Disord. 26(1), 6-16 (2002).
175 Gesta S, Simon MF, Rey A et al. Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis. J. Lipid Res. 43(6), 904-910 (2002).
176 Moore HP, Silver RB, Mottillo EP, Bernlohr DA, Granneman JG. Perilipin targets a novel pool of lipid droplets for lipolytic attack by hormone-sensitive lipase. J. Biol. Chem. 280(52), 43109-43120 (2005).
177 Martinez-Botas J, Anderson JB, Tessier D et al. Absence of perilipin results in leanness and reverses obesity in Lepr(db/db) mice. Nat.Genet. 26(4), 474-479 (2000).
178 Wang Y, Sullivan S, Trujillo M et al. Perilipin expression in human adipose tissues: effects of severe obesity, gender, and depot. Obes. Res. 11(8), 930-936 (2003).
179 Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44(8), 863-870 (1995).
180 Corella D, Qi L, Sorli JV et al. Obese subjects carrying the 11482G>A polymorphism at the perilipin locus are resistant to weight loss after dietary energy restriction. J. Clin. Endocrinol. Metab. 90(9), 5121-5126 (2005).
181 Franckhauser S, Munoz S, Pujol A et al. Increased fatty acid re-esterification by PEPCK overexpression in adipose tissue leads to obesity without insulin resistance. Diabetes 51(3), 624-630 (2002).
182 Beale EG, Hammer RE, Antoine B, Forest C. Glyceroneogenesis comes of age. FASEB J. 16(13), 1695-1696 (2002).
183 Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis 155(2), 269-281 (2001).
184 Kaser S, Sandhofer A, Foger B et al. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44(9), 1111-1117 (2001).
185 Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23(10), 1857-1862 (2003).
186 Kaser S, Laimer M, Sandhofer A, Salzmann K, Ebenbichler CF, Patsch JR. Effects of weight loss on PLTP activity and HDL particle size. Int. J. Obes. Relat. Metab. Disord. 28(10), 1280-1282 (2004).
187 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
188 Lichtenstein AH, Ausman LM, Jalbert SM et al. Efficacy of a Therapeutic Lifestyle Change/Step 2 diet in moderately hypercholesterolemic middle-aged and elderly female and male subjects. J. Lipid Res. 43(2), 264-273 (2002).
189 Takamiya T, Kadowaki T, Zaky WR et al. The determinants of plasma plasminogen activator inhibitor-1 levels differ for American and Japanese men aged 40-49. Diabetes Res. Clin. Pract. 72(2), 176-182 (2005).
190 Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51(4), 1131-1137 (2002).
191 Morange PE, Lijnen HR, Alessi MC, Kopp F, Collen D, Juhan-Vague I. Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity. Arterioscler. Thromb. Vasc. Biol. 20(4), 1150-1154 (2000).
192 Liang X, Kanjanabuch T, Mao SL et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am. J. Physiol. Endocrinol. Metab. 290(1), E103-E113 (2006).
193 Hamalainen H, Ronnemaa T, Virtanen A et al. Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study. Diabetologia 48(11), 2248-2253 (2005).
194 Koerner A, Kratzsch J, Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab. 19(4), 525-546 (2005).
195 Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436(7049), 356-362 (2005).
196 Burri BJ, Neidlinger TR, Van Loan M, Keim NL. Effect of low-calorie diets on plasma retinol-binding protein concentrations in overweight women. J. Nutr. Biochem. 1(9), 484-486 (1990).
197 Gillmer MD. Mechanism of action/effects of androgens on lipid metabolism. Int. J. Fertil. 37(Suppl. 2) 83-92 (1992).
198 Niskanen L, Laaksonen DE, Punnonen K, Mustajoki P, Kaukua J, Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes. Metab. 6(3), 208-215 (2004).
199 Kaukua J, Pekkarinen T, Sane T, Mustajoki P. Sex hormones and sexual function in obese men losing weight. Obes. Res. 11(6), 689-694 (2003).
200 Stanik S, Dornfeld LP, Maxwell MH, Viosca SP, Korenman SG. The effect of weight loss on reproductive hormones in obese men. J. Clin. Endocrinol. Metab. 53(4), 828-832 (1981).
201 Strain GW, Zumoff B, Miller LK et al. Effect of massive weight loss on hypothalamic-pituitary-gonadal function in obese men. J. Clin. Endocrinol. Metab. 66(5), 1019-1023 (1988).
202 Pasquali R, Casimirri F, Melchionda N et al. Weight loss and sex steroid metabolism in massively obese man. J. Endocrinol. Invest. 11(3), 205-210 (1988).
203 Escobar-Morreale HF, Botella-Carretero JI, varez-Blasco F, Sancho J, San Millan JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J. Clin. Endocrinol. Metab. 90(12), 6364-6369 (2005).
204 Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet. Gynecol. Clin. North Am. 28(1), 85-97 (2001).
205 Zhang S, Kim KH. TNF-[alpha] inhibits glucose-induced insulin secretion in a pancreatic [beta]-cell line (INS-1). FEBS Lett. 377(2), 237-239 (1995).
206 Berndt J, Kloting N, Kralisch S et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54(10), 2911-2916 (2005).
207 Kloting N, Berndt J, Kralisch S et al. Vaspin gene expression in human adipose tissue: Association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339(1), 430-436 (2006).
208 Hida K, Wada J, Eguchi J et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl Acad. Sci. USA 102(30), 10610-10615 (2005).
209 Chen MP, Chung FM, Chang DM et al. Elevated Plasma Level of Visfatin/Pre-B Cell Colony-Enhancing Factor in Patients with Type 2 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 91(1), 295-299 (2006).
210 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91(4), 1578-1581 (2006).
211 Bays HE, Dujovne CA. Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr. Atheroscler. Rep. (In Press) (2006).
212 Bays H, Stein EA. Pharmacotherapy for dyslipidaemia-current therapies and future agents. Expert Opin. Pharmacother. 4(11), 1901-1938 (2003).
213 Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468), 1389-1397 (2005). * Rimonabant may have favorable effects upon metabolic parameters in overweight patients beyond weight loss alone.
214 Hsieh CJ, Wang PW, Liu RT et al. Orlistat for obesity: benefits beyond weight loss. Diabetes Res. Clin. Pract. 67(1), 78-83 (2005). * Orlistat may have favorable effects upon metabolic parameters in overweight patients beyond weight loss alone.
215 Bays HE. The melanocortin system as a therapeutic treatment target for adiposity and adiposopathy. Drugs in R & D (In Press) (2006).
216 Bartness TJ, Kay Song C, Shi H, Bowers RR, Foster MT. Brain-adipose tissue cross talk. Proc. Nutr. Soc. 64(1), 53-64 (2005).
217 Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am. J. Physiol. 277(6 Pt 1), E1130-E1141 (1999).
218 Blaak EE, Wolffenbuttel BH, Saris WH, Pelsers MM, Wagenmakers AJ. Weight reduction and the impaired plasma-derived free fatty acid oxidation in type 2 diabetic subjects. J. Clin. Endocrinol. Metab. 86(4), 1638-1644 (2001).
219 Kelley DE Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a re-examination. Diabetes 49677-683 (2000).
220 Tomas F, Kelly M, Xiang X et al. Metabolic and hormonal interactions between muscle and adipose tissue. Proc. Nutr. Soc. 63(2), 381-385 (4).
221 Finn PF, Dice JF. Proteolytic and lipolytic responses to starvation. Nutrition 22(7-8), 830-844 (2006).
222 Chu CA, Sherck SM, Igawa K et al. Effects of free fatty acids on hepatic glycogenolysis and gluconeogenesis in conscious dogs. Am. J. Physiol. Endocrinol. Metab. 282(2), E402-E411 (2002).
223 Arner P. Regional adipocity in man. J. Endocrinol. 155(2), 191-192 (1997).
224 Wajchenberg BL, Giannella-Neto D, da Silva ME, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm. Metab. Res. 34(11-12), 616-621 (2002).
225 Park KG, Park KS, Kim MJ et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res. Clin. Pract. 63(2), 135-142 (2004).
226 Pedersen SB, Kristensen K, Hermann PA, Katzenellenbogen JA, Richelsen B. Estrogen controls lipolysis by up-regulating [alpha]2A-adrenergic receptors directly in human adipose tissue through the estrogen receptor [alpha]. Implications for the female fat distribution. J. Clin. Endocrinol. Metab. 89(4), 1869-1878 (2004).
227 McCarty MF. A paradox resolved: the postprandial model of insulin resistance explains why gynoid adiposity appears to be protective. Med. Hypotheses 61(2), 173-176 (2003). ** If accompanied by favorable functionality, the addition of fat may improve or provide 'protection' against certain metabolic diseases.
228 Reynisdottir S, Dauzats M, Thorne A, Langin D. Comparison of hormone-sensitive lipase activity in visceral and subcutaneous human adipose tissue. J. Clin.Endocrinol.Metab. 82(12), 4162-4166 (1997).
229 Mohamed-Ali V, Goodrick S, Rawesh A et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-[alpha], in vivo. J. Clin.Endocrinol.Metab. 82(12), 4196-4200 (1997).
230 Raz I, Eldor R, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab. Res. Rev. 21(1), 3-14 (2005).
231 Rieusset J, Auwerx J, Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor [gamma] with rosiglitazone (BRL 49653) in human adipocytes. Biochem. Biophys. Res. Commun. 265(1), 265-271 (1999).
232 Ebeling P, Teppo AM, Koistinen HA, Koivisto VA. Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes. Metabolism 50(3), 283-287 (2001).
233 Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes. Metab. 7(6), 675-691 (2005).
234 Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 148(3), 293-300 (2003).
235 Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr. Med. Res. Opin. 21(3), 457-468 (2005).
236 Hung YJ, Chen YC, Pei D et al. Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes. Diabet. Med. 22(8), 1024-1030 (2005).
237 Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353(20), 2121-2134 (2005).
238 Wu Z, Xie Y, Morrison RF, Bucher NL, Farmer SR. PPAR-[gamma] induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBP[alpha] during the conversion of 3T3 fibroblasts into adipocytes. J. Clin. Invest. 101(1), 22-32 (1998).
239 Unger RH. Lipotoxic diseases. Annu. Rev. Med. 53, 319-336 (2002). * Insufficiency of fat function through insufficiency of fat can also result in lipotoxicity.
240 van Tits LJ, Rioglu-Oral E, Sweep CG, Smits P, Stalenhoef AF, Tack CJ. Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity. Neth. J. Med. 63(7), 250-255 (2005).
241 Yesilbursa D, Serdar A, Heper Y et al. The effect of orlistat-induced weight loss on interleukin-6 and C-reactive protein levels in obese subjects. Acta Cardiol. 60(3), 265-269 (2005).
242 Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41(2), 393-398 (1992).
243 Drent ML, Popp-Snijders C, Ader HJ, Jansen JB, van der V. Lipase inhibition and hormonal status, body composition and gastrointestinal processing of a liquid high-fat mixed meal in moderately obese subjects. Obes. Res. 3(6), 573-581 (1995).
244 Baranowska B, Wolinska-Witort E, Martynska L et al. Sibutramine therapy in obese women - effects on plasma neuropeptide Y (NPY), insulin, leptin and [beta]-endorphin concentrations. Neuro. Endocrinol. Lett. 26(6), 675-679 (2005).
245 Poirier B, Bidouard JP, Cadrouvele C et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes. Metab. 7(1), 65-72 (2005).
246 Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P. Anandamide induced PPAR[gamma] transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517(3), 174-181 (2005).
247 Simon MF, Daviaud D, Pradere JP et al. Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor [gamma]2. J. Biol. Chem. 280(15), 14656-14662 (2005).
248 Rissanen P, Vahtera E, Krusius T, Uusitupa M, Rissanen A. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int. J. Obes. Relat. Metab. Disord. 25(2), 212-218 (2001).
249 Jung HS, Youn BS, Cho YM et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54(3), 314-320 (2005).
250 Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116(1-2), 52-61 (2005).
251 Hammarstedt A, Pihlajamaki J, Sopasakis VR et al. Visfatin is an adipokine but it is not regulated by thiazolidinediones. J. Clin. Endocrinol. Metab. 91(3), 1181-1184 (2006).
252 Choi KC, Ryu OH, Lee KW et al. Effect of PPAR-[alpha] and -[gamma] agonist on the expression of visfatin, adiponectin, and TNF-[alpha] in visceral fat of OLETF rats. Biochem. Biophys. Res. Commun. 336(3), 747-753 (2005).
253 Visser L, Zuurbier CJ, van Wezel HB, van der Vusse GJ, Hoek FJ. Overestimation of plasma nonesterified fatty acid concentrations in heparinized blood. Circulation 110(13), E328 (2004).
254 Diep QN, El Mabrouk M, Cohn JS et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-[gamma]. Circulation 105(19), 2296-2302 (2002).
255 Cota D, Marsicano G, Tschop M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112(3), 423-431 (2003).
256 Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C. Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. Endocr. J. 52(3), 299-308 (2005).
257 Vierhapper H, Nowotny P, Waldhausl W. Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 52(2), 230-232 (2003).
258 Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL. Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 90(2), 729-733 (2005).
259 Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil. Steril. 80(5), 1199-1204 (2003).
260 Pang XH, Gu W. [Association of serum sex hormone-binding globulin with type 2 diabetes]. Zhejiang. Da. Xue. Xue. Bao. Yi. Xue. Ban. 33(1), 60-64 (2004).
261 Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated receptor [gamma] ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res. 60(6), 1604-1608 (2000).
301 Bays H. Adiposopathy causes the metabolic syndrome: the beginning or end of a controversy? IAS commentary. Home of the International Atherosclerosis Society www.athero.org
302 Bays H. Adiposopathy homepage. www.lmarc.com/Index%20Adiposopathy%20Frames.htm
|
Language: | English.
|
Document Type: | Review.
|
ISSN: | 1477-9072
|
NLM Journal Code: | 101182328
|
DOI Number: | https://dx.doi.org/10.1586/14779...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|